Showing 20 of 203 recruiting trials for “combined-hepatocellular-carcinoma-and-cholangiocarcinoma”
Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer
👨⚕️ Eric Roeland, M.D., FAAHPM, FASCO, OHSU Knight Cancer Institute📍 1 site📅 Started Jul 2024View details ↗
RecruitingNCT06505486 ↗
GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC
👨⚕️ Jia-yan Ni, M.D., Sun Yat-sem Memorial Hospital, Sun Yat-sen University📍 1 site📅 Started Jul 2024View details ↗
Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery
👨⚕️ Hop S Tran Cao, University of Texas MD Anderson Cancer Center LAO📍 58 sites📅 Started Jul 2024View details ↗
RecruitingNCT06643208 ↗
D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC
👨⚕️ Maolin Yan, Doctor, Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital📍 1 site📅 Started Jul 2024View details ↗
RecruitingNCT06430983 ↗
Recurrent Liver Cancer: Reconceptualization and Reevaluation
A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC
The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer
Combined HAIC, Lenvatinib and Pucotenlimab As Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
Robotically Assisted Surgery For Perihilar Cholangiocarcinoma: A Prospective Study
Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma
Evaluating a Community-Based Behaviour Change Communication Model to Prevent Cholangiocarcinoma in Khon Kaen, Thailand
Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)
Enrolling by InvitationNCT06474091 ↗
Liquid Biopsy MonitORing Of CholangioCarcinOma for Treatment Response and Prognostic Outcomes (MOROCCO)
Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
🏥 Second Affiliated Hospital of Guangzhou Medical University📍 1 site📅 Started May 2024View details ↗
Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy
Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma
Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma
Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)
RecruitingNCT06342414 ↗
An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →